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Background to cell therapy
Ischaemia is characterised by a reduction in oxygen 
supply to tissues and organs, usually as a result of blood 
vessel constriction or obstruction. Th is leads to hypoxia 
and tissue damage as a consequence of the build up of 
waste metabolites and may result in cell death [1]. Many 
important diseases are characterised by acute or chronic 
ischaemia, which aﬀ ect millions of people each year and 
represent a considerable morbidity, mortality and eco-
nomic cost to healthcare systems worldwide [2].
Th e use of cell therapy for vascular regeneration oﬀ ers 
an exciting new prospect in regenerative medicine. 
Indeed, in the ﬁ eld of vascular biology there are already a 
considerable number of ongoing clinical trials using a 
cytotherapy for ischaemic diseases such as myocardial 
ischaemia and peripheral limb ischaemia [3,4]. However, 
the delivery of the correct cell type to the precise area of 
injury or vascular insuﬃ  ciency is diﬃ  cult and many 
factors need to be considered.
One such factor to consider is eﬃ  cacy. Cells for 
vascular therapy must be able to home to ischaemic or 
damaged tissue and engage in vessel formation alone or 
in unison with resident vascu lature to achieve a con-
trolled and functional reperfusion event, without causing 
pathological angiogenesis (for example, proliferative 
retino pathy in the vitreous of the eye).
Th e timing of delivery and cell numbers also require 
consideration. A cell therapy approach should be aimed 
at promoting re vascularisation of ischaemic tissue. Th ere 
is a therapeutic window in which to deliver the cells, to 
avoid extensive tissue damage, ﬁ brosis and necrosis. Th e 
evaluation of the most suitable timing of cell delivery as 
well as the number of cells needed to integrate into 
resident vascu la ture and promote revascularisation of 
speciﬁ c tissues requires careful optimisation and 
evaluation.
A third factor is the administration route. An important 
point to consider when examining cell recruitment is the 
mode of cell delivery. Previous studies using vascular 
progenitor cells have shown that local delivery results in 
increased homing as the cells are directly delivered to the 
ischaemic area or tissue environment that is experiencing 
the disease [5]. A systemic delivery strategy is based on 
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the capacity of the cells to be mobilised and directed via 
chemokines to the ischaemic area; however, the drawback 
of this approach is that this may result in cells localising 
to non-target organs such as the liver, kidneys, spleen 
and lung.
Finally, one should consider cell choice, a critical aspect 
of any cell therapy. Th e correct cell must be chosen for its 
phenotype, cell characteristics and biological functions. 
Th is is impor tant, because some ischaemic diseases have 
added complicating factors such as a hypoxic and pro-
inﬂ am ma tory microenvironment. In this situation, in-
ject ing any cell with the predisposition to switch to an 
inﬂ ammatory phenotype could exacerbate the underlying 
pathology [6].
Bone marrow (BM) contains a great variety of stem and 
progenitor cells, such as haematopoietic stem cells 
(HSCs), mesenchymal stem cells (MSCs) and endothelial 
progenitor cells (EPCs). BM therefore represents a 
relevant source of vascular progenitor cells. Clinical trials 
have tested BM-derived unfractionated mononucleated 
cells as a therapy for various ischaemic disorders such as 
heart disease [7]; however, results from these studies 
have generated conﬂ icting results. Th is is largely due to 
the fact that BM contains a heterogeneous mix of cells, 
making the evaluation of the relative contribution of 
speciﬁ c cell types very diﬃ  cult. Two other accessible 
sources for isolation of stem/progenitor cells are adult 
peripheral blood and umbilical cord blood.
Th ere are many cell types currently being considered 
for cytotherapies in the context of ischaemic diseases 
(Figure 1). Such cells include MSCs [8], multipotent adult 
progenitor cells (MAPCs) [9], EPCs [10], pluri potent 
embryonic stem cells (ESCs) [11], and induced 
pluripotent stem cells (iPSCs) [12] (Table 1).
Th e diﬀ erentiation potential of MSCs and MAPCs into 
mural cells such as smooth muscle cells (SMCs) and 
pericytes has been reported [13,14]. Mural cells play a 
key role in the context of vascular regeneration by 
providing structural support to the vasculature, and 
regulating new blood vessel formation, maturation and 
stabilisation. It has been suggested that building a new 
blood vessel requires the  interaction of both endothelial 
cells and mural cells. Th e present review will particularly 
focus on the endothelial cell component of cytotherapies 
for vascular regeneration. Th e three main cell candidates 
are ESCs, iPSCs and EPCs.
Pluripotent stem cells
Pluripotent stem cells have generated widespread atten-
tion in the last decade due to their capacity to become 
virtually any cell in the body. With the exception of extra-
embryonic tissue, pluripotent stem cells have the poten-
tial to diﬀ erentiate into derivatives of all three germ 
layers.
Embryonic stem cells
ESCs are derived from the inner cell mass of a pre-
implantation blastocyst-stage embryo, a process that 
results in the loss of the embryo. Th is source presents an 
ethical dilemma for many, but recent improvements have 
demonstrated that ESCs can be generated from a single 
blastomere, without damage to the embryo [15]. Beyond 
the ethics dimension, there are major concerns about the 
therapeutic use of ESCs due to an inherent risk of tumour 
or teratoma formation [16].
Analysis of human ESCs diﬀ erentiation suggests that 
endothelial cells originate via a primitive haemangio blast 
precursor that can give rise to cells of both 
haematopoietic and endothelial fate [17]. hESC-ECs have 
been diﬀ erentiated using a variety of methods, including 
co-cultures with stromal layers [18] or in suspension 
culture as embryoid bodies [17,19]. Th ese hESC-ECs 
express a variety of endothelial markers (PECAM1, 
CD34, KDR and VE-CAD), uptake DiI-Ac-LDL, display 
the typical cobble stone morphology and form tubes in 
Matrigel [20]. Trans plantation of hESC-ECs has shown 
that these cells can evoke reperfusion in animal models 
of hind limb ischaemia [21,22] and ischaemic heart 
disease, demonstrating their promising thera peutic 
poten tial in promoting neovascularisation [23]. However, 
before these cells can be used as a therapy for patients 
suﬀ ering with ischaemic vascular disease, the generation 
of immune-compatible transplants needs to be addressed 
so that clinical application can be realised.
Induced pluripotent stem cells
Even following the transplantation of closely matched 
graft cells, a patient is still likely to require immuno-
suppressive therapy. Autologous cell transplantation is 
therefore highly desirable to overcome immunogenic 
mismatch between host and graft.
In 1989, Weintraub and colleagues [24] demonstrated 
that it was possible to drive ﬁ broblast cell fate into 
muscle, by expressing the transcription factor MyoD. 
Th is phenomenon was later exploited by Takahashi and 
Yamanaka in mouse ﬁ broblasts [25], and later in human 
cells to induce the ‘reprogramming’ of adult skin ﬁ bro-
blasts to a pluripotent state using C-MYC, KLF4, 
OCT3/4 and SOX2 [26]. Th ese cells, known as iPSCs, 
have many of the advantages of ESCs, and critically can 
be generated in a patient-speciﬁ c manner.
It is possible to diﬀ erentiate endothelial cells from 
human iPSCs; diﬀ erentiation protocols that have been 
established for human ESCs are applicable to iPSCs. 
Th ese include, culturing iPSCs with OP9 as feeder cells 
[27], embryoid body assays [28] and exposure to vascular 
endothelial growth factor [29]. Th ese culture conditions 
initiate diﬀ erentiation to an endothelial phenotype with 
iPSC-ECs displaying typical endothelial characteristics, 
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Figure 1. Schematic representing the role of stem and progenitor cells in vascular repair. Multiple stem and progenitor cells may contribute 
to vascular repair in vivo. Both embryonic stem cells (ESCs; blue) and induced pluripotent stem cells (iPSCs; orange) can be diff erentiated 
into vascular cells and may be utilised in vivo as endothelial cells with the potential to engraft into damaged or ischaemic host vasculature. 
Mesenchymal stem cells (MSCs; pink) have the potential to diff erentiate into mural cells such as pericytes and smooth muscle cells. This would be 
particularly useful in ischaemic tissue as mural cells are essential for stabilisation of newly formed vessels and communicate closely with endothelial 
cells through adherens junctions. The protein N-cadherin is depicted as pink diamonds. Multipotent adult progenitor cells (MAPCs purple) may 
also be diff erentiated into endothelial cells to aid vascular repair and reduce ischaemia. Early endothelial progenitor cells/myeloid angiogenic cells 
(eEPCs/MACs; red) play a paracrine role by secreting pro-angiogenic growth factors and cytokines (yellow triangles and blue squares) to stimulate 
vascular regeneration. Outgrowth endothelial cells (OECs; green) display a typical endothelial phenotype and have clinical potential for ischaemic 
disease as they home to ischaemic areas and directly integrate into denuded endothelium.
Table 1. Characteristics of stem/progenitor cells that can be used for therapeutic revascularisation of ischaemic tissue
   Risk of Capacity to Engraftment/
  Proliferative tumour diff erentiate angiogenic
Cell type potential formation into vascular cells potential in vivo 
Pluripotent stem cells    
 Embryonic stem cells +++ +++ + +
 Induced pluripotent stem cells +++ +++ + +
Adult stem cells    
 Mesenchymal stem cells + +/– ++ ++
 Multipotent adult progenitor cells ++ +/– ++ ++
Endothelial progenitor cells    
 Early endothelial progenitor cells +/– + +/– +
 Outgrowth endothelial cells ++ +/– +++ +++
+, ++, +++, Weak/low, moderate and high potential, respectively; +/-, little or no potential
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including capillary formation in Matrigel and expression 
of endothelial markers such as CD31, KDR, CD144 and 
endothelial nitric oxide synthase. A recent study has 
demonstrated the therapeutic poten tial of iPSCs: when 
injected into an ischaemic hind limb model, iPSCs were 
shown to increase capillary density and improve blood 
perfusion [12].
Th e past 5  years have seen major advances in the 
poten tial translation of iPSCs to the clinic, including 
improvements in reprogramming eﬃ  ciencies, alterna-
tives to skin ﬁ broblasts, and integration-free reprogram-
ming transgene expression methods such as adenovirus, 
minicircle DNA, episomes and synthetic proteins and 
mRNA [30]. However, several further issues must be 
resolved before iPSCs can be used clinically. Th ere are 
concerns with iPSCs regarding the use of the proto-
oncogene c-myc, and insertion mutagenesis due to the 
use of retroviral sequences. Th ere are also concerns 
regarding the tumourigenic potential of diﬀ er en tiated 
PSCs [31]. Additionally, there are issues surrounding the 
genetic and epigenetic integrity of the iPSCs and also the 
true nature of their immunogenic status. For example, 
recent reports have concluded that human iPSCs carry 
an increased muta tional load in the form of karyotypic 
abnormalities and the accumulation of somatic protein 
coding point mutations relative the parent cell line used 
to generate them [32,33]. Th ese mutations are presumed 
to be due to ‘reprogram ming stresses’. However, in these 
studies the genomes of clonally derived iPSCs were being 
compared with reference genomes generated from a 
polyclonal parent population and therefore, the 
identiﬁ cation of bona ﬁ de mutations could have been 
hampered. Furthermore, it must be noted that iPSCs 
appear to retain an epigenetic memory of their former 
cell type [34]. Th e inﬂ uence of this on the diﬀ erentiation 
capacity of the iPSCs is not yet clear; for example, 
persistence of epigenetic memory in iPSCs may be 
limited during sequential passaging and time in culture. 
However, this epigenetic memory may be advantageous if 
we consider deriving iPSCs from vascular cells in order to 
enhance endothelial cell and smooth muscle cell 
production from iPSCs.
Adult stem/progenitor cells
Lineage-committed multipotent or unipotent progenitor 
cells may represent a more feasible cell choice for the 
treatment of vascular disease. Th e beneﬁ ts of using adult-
derived progenitors are that they allow for autologous 
therapy and they are lineage restricted, and thus probably 
are much safer than pluripotent stem cells with fewer 
ethical concerns. Many deﬁ ned populations are already 
being tested for safety and feasibility in clinical trials, so 
adult progenitors cells are likely to be the ﬁ rst cells 
translated to the clinical setting.
Endothelial progenitor cells
EPCs have been extensively studied as progenitor cells 
capable of contributing to neovascularisation. Th ese 
cells may also have potential as diagnostic/prognostic 
bio markers for cardiovascular and cerebrovascular 
disease. Th ere appears to be an inverse correlation 
between the number of circulating EPCs and the number 
of deaths from cardiovascular events [35]; furthermore, 
they can also be used as tools to study vascular disease 
[36]. EPCs may be isolated from peripheral blood, BM 
and umbilical cord blood. Although they represent only 
a minor population (0.05 cells/ml blood) relative to the 
cell populations in whole blood, EPCs have been shown 
to play a major role in therapeutic angiogenesis and 
vascular repair in various ischaemic tissues; and 
represent an important candidate for a cell therapy 
approach [37].
Th e ﬁ rst putative EPCs were isolated from human 
peripheral blood in 1997 by Asahara in a seminal paper 
that appeared to demonstrate postnatal vasculogenesis 
[38]. Th is team, lead by Jeﬀ rey Isner, used a combination 
of cell-sorting approaches, using CD34 as a marker for 
EPC selection, followed by subsequent plating on 
ﬁ bronectin to isolate EPCs. Th ese cells were found to 
express endothelial cell-like markers CD31, VEGFR2, 
Tie-2 and E-selectin after 7  days in culture, indicating 
their diﬀ erentiation towards an endothelial phenotype. 
Importantly, this study also demonstrated functionality; 
when the pre-labelled EPCs were injected into the 
ischaemic limbs of nude mice, they appeared to target 
avascular zones within the diseased tissue and participate 
in neovascularisation, thus providing evidence of EPCs 
angiogenic capacity. Since Asahara’s discovery, modiﬁ ed 
versions of this isolation procedure have been used for 
isolating EPCs [39] and it is now evident that these EPCs 
are likely to be a heterogeneous mix of endothelial and 
haematopoietic cells that have been shown to comprise 
monocytes and macrophages [40].
Over the last decade there have been contradictory 
reports surrounding the precise nature of EPCs as pre-
clinical and clinical investigations evaluating the 
therapeutic potential of EPCs have yielded inconsistent 
results [10,41] Th is is largely due to the fact that EPCs 
lack a uniform deﬁ nition and there are no deﬁ nitive 
markers used to isolate an EPC [42]. It is now accepted 
that there are at least two deﬁ nitive EPC subsets that can 
be isolated in vitro. One cell type appears after a few days 
in culture and these cells are called early EPCs (eEPCs), 
while the other type of cells, appearing much later, are 
called outgrowth endothelial cells (OECs) or endothelial 
colony-forming cells (ECFCs) [37]. Th e biological 
properties of these two cells, their potential role in 
vascular repair and their potential for cytotherapy will be 
further discussed.
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Early endothelial progenitor cells
Th e early EPC population is now generally well recog-
nised not to be endothelial in origin [43]. Although this 
subset of circulat ing cells express typical endothelial 
markers such as CD31, VEGFR2 and Tie2, these markers 
are not necessarily endothelial speciﬁ c, and mononuclear 
cells in culture may acquire these markers through 
platelet microparticle uptake [44]. Furthermore, eEPCs 
also express haematopoietic markers CD14 and CD45 
and morphologically appear in culture as spindle-shaped 
cells, with a low proliferative potential, and bear no 
resemblance to the cobblestone appearance of endothelial 
cells. Recent research including work from our own 
laboratory, has demonstrated that early EPCs are distinct 
from endothelial cells, in terms of their gene expression, 
proteomic proﬁ le and ultrastructure [43]. We have shown 
that eEPCs represent haematopoietic cells with a 
molecular ﬁ ngerprint that resembles pro-angiogenic M2 
macrophages [45]. Given all this evidence we feel that the 
term eEPC is no longer accurate to describe this popu-
lation of cells, and we recently coined the term myeloid 
angiogenic cells (MACs) as a more ﬁ tting description of 
the true identity of these cells.
Despite their haematopoietic origin, MACs do have 
therapeutic value; they appear to stimu late angiogenesis 
in a paracrine manner [46]. MACs home to areas of 
ischaemia and stimulate regeneration of existing vascu-
lature through the secretion of pro-angiogenic cytokines 
and growth factors such as IL-8, hepatocyte growth 
factor, insulin-like growth factor and granulocyte colony-
stimulating factor [45,47]. While these cells do not in-
corporate directly into the vasculature, they remain 
proximal or loosely attached to the damaged tissue in a 
perivascular position. In this manner, MACs have been 
shown to facilitate vascular repair and promote reper-
fusion in critical limb ischaemia, ischaemic retinopathy 
and after myocardial infarction [45,48,49]. However, it 
must be noted that because these cells are linked to 
macrophages they may be highly plastic, and therefore in 
the presence of an inﬂ ammatory or hypoxic tissue 
environ ment they may enhance inﬂ ammation [6]. Th ere-
fore, careful consideration of the source of the cells and 
the milieu must therefore be taken into account if these 
cells are to be used clinically. It may be more advan-
tageous to fully characterise mechanisms responsible for 
MACs paracrine eﬀ ects so that respective approaches 
can be established to promote vascular regeneration. Th is 
will include use of conditioned medium, use of recom bi-
nant proteins and stimulation of pro-angiogenic pathways.
Outgrowth endothelial progenitor cells
OECs, also known as ECFCs or late EPCs, represent bona 
ﬁ de endothelial progenitor cells [50]. A classic method 
for obtaining OECs is in vitro culture of the mono nuclear 
fraction of blood at high density on collagen. Using this 
method, OEC colonies start appear ing from 3 to 5 weeks 
and bear a typical cobblestone-shaped morphology. 
Research from our own group using genome-wide trans-
criptomics, proteomics and ultra struc tural evaluation 
has demonstrated OECs intrinsic endothelial identity. 
OECs have a remarkably high pro liferative capacity in 
comparison with circulating endo thelial cells and main-
tain an endothelial phenotype with ex vivo long-term 
expansion [43].
Functionally, OECs display endothelial characteristics. 
Previous studies have highlighted the in vitro angiogenic 
potential of OECs; they are capable of integrating into 
pre-existing vessels and of de novo tube formation in 
several in vitro models [51,52]. However, a rigorous test 
for true endothelial potential is direct engraftment in 
vivo. Various groups, including our own, have demon-
strated that OECs possess in vivo potential by directly 
aiding vascular repair and forming well-perfused vascu-
lature in various in vivo models [51,53]. Recently, we 
demonstrated OECs therapeutic potential for retinal 
ischaemia when they were delivered intravitreally into a 
mouse model and homed speciﬁ cally to ischaemic areas 
within the central retina and integrated directly within 
the host vasculature, assisting in vascular remodelling by 
forming vascular tubes [54]. Importantly, this study 
demonstrated func tional beneﬁ ts such as a signiﬁ cant 
decrease in ischaemia and a concomitant increase in 
normal vasculature. Although this study examined the 
therapeutic beneﬁ t of OECs over a relatively short time 
period of 72 hours, the long-term eﬀ ectiveness and safety 
of OECs has also been assessed in a porcine model of 
acute myocardial infarc tion [55]. Furthermore, OECs 
injected into the systemic circulation of non-obese 
diabetic (NOD)/severe combined immuno deﬁ cient 
(SCID) mice are able to lodge and survive in nine 
diﬀ erent vascular beds for up to 7  months after intra-
venous tail vein injection, without inducing throm bosis 
or infarcts [56]. Th is ﬁ nding highlights the potential 
beneﬁ ts of a novel cytotherapy using a well-deﬁ ned 
population of OECs for patients with ischaemic-related 
pathology.
However, it must be noted that OECs have some limita-
tions when compared with ESCs/iPSCs. Firstly, OECs 
lack a unique surface marker to identify them, and this 
limits their isolation using a cell-sorting approach. A 
panel of surface markers are therefore needed to charac-
terise OECs for expression of endothelial markers such as 
CD146, VE-cadherin, CD31 and VEGFR2. Th ey also 
remain a relatively diﬃ  cult cell to isolate using in vitro 
culture methodologies. OEC colonies can take quite a 
long time to emerge, with some colonies taking up to 1 
month to appear in culture. Once isolated, however, OEC 
colonies can be expanded to yield a pure population of 
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cells with a high proliferation rate; for example, some 
cord blood-derived colonies have been expanded up to a 
level of 80 population doublings in just 90 days.
Conclusion
Th ere is considerable therapeutic potential in using a 
cell-based approach to treat vasodegenerative disorders 
[57]. Indeed, various stem cells and adult progenitors 
have been highlighted as having important vasoreparative 
and regenerative potential in vascular medicine [58]. 
Some of these progenitor cells are already being used in 
clinical trials for the treatment of ischaemic diseases such 
as limb and cardiac ischaemia and are showing promising 
results [4,59]. Th is review has examined the clinical 
potential of various cell-based therapeutic approaches 
that may be applied to regenerate defunct or damaged 
vasculature and restore blood ﬂ ow. Th ere are many 
options of which cell types to use, although ultimately the 
best options will need to be tailored for disease type, for 
the precise nature of repair or vessel regrowth being 
sought and for whether the therapeutic regime is 
autologous or allogeneic. Ideally, once delivered, these 
cells should have an unambiguous fate with precise 
reparative and vessel formation properties in vivo whilst 
having limited replicative potential, thereby reducing the 
neoplastic risk associated with many stem cell therapies. 
With a focused research eﬀ ort in the coming years, there 
is every expectation that cell therapy can become an 
important and highly beneﬁ cial treatment option for 
ischaemic disease.
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